Evidence map›Paper›PMID 40688586›Full record

ArticleOncology letters2025

Silymarin induces multiple myeloma cell apoptosis by inhibiting the JAK2/STAT3 signaling pathway.

Haiyun Liu, Tingting Liu, Junquan Zeng, Quangang Fang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Haiyun LiuDepartment of Clinical Laboratory, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nangchang, Jiangxi 330000, P.R. China.
Tingting LiuDepartment of Hematology, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nangchang, Jiangxi 330000, P.R. China.
Junquan ZengDepartment of Hematology, The Affiliated Hospital of Jinggangshan University, Ji'an, Jiangxi 343000, P.R. China.
Quangang FangDepartment of Clinical Laboratory, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nangchang, Jiangxi 330000, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple myeloma (MM) is a malignant tumor that originates in the plasma cells of the bone marrow, interfering with the production of healthy blood cells and causing notable damage to bones and other tissues. Currently, the treatment options for MM are limited and often fail to provide effective and well-tolerated solutions. Silymarin, a primary active compound found in the dried fruit of

Indexed as

apoptosisJAK2/STAT3 signaling pathwaymolecular dockingmultiple myelomanetwork pharmacologysilymarin

Identifiers

PMID40688586
PMCPMC12273804

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.